Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of once-daily HRS9531 tablets in adults with obesity
CTR20250596Phase 2Completed
- Sponsor
- Fujian Shengdi Pharmaceuticals
- Start
- Apr 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of HRS9531 in obesity, sponsored by Fujian Shengdi Pharmaceuticals. Started Apr 2025; status: completed.
02
Drugs
HRS9531
03
Conditions
obesity
Beyond the preview
Go deeper on CTR20250596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250596.